New drug duo aims to stop kidney rejection in its tracks

NCT ID NCT06918990

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests two drugs, carfilzomib and belatacept, in 25 kidney transplant recipients who have a type of rejection called antibody-mediated rejection. The goal is to see if the combination is safe and can reduce harmful antibodies or improve kidney function over a year. Participants will have regular biopsies and blood tests to track their response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: carfilzomib and belatacept
What this could lead to: If successful, this could offer a new treatment option for kidney transplant patients experiencing antibody-mediated rejection, potentially preserving graft function longer.
What could go wrong: This is a very early Phase 1 trial with only 25 participants, so safety and efficacy are not yet established. The drugs may cause serious infections or infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIBODY-MEDIATED KIDNEY TRANSPLANT REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute transplant rejection transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANT REJECTION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cleveland Clinic
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Duke University
NOT_YET_RECRUITING

Durham, North Carolina, 27710, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Mayo Clinic Arizona
NOT_YET_RECRUITING

Phoenix, Arizona, 85054, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
NYU Langone Health
RECRUITING

New York, New York, 10016, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Northwestern University, Feinberg School of Medicine
NOT_YET_RECRUITING

Chicago, Illinois, 60611, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
UCLA Medical Center (Site #: 71123)
NOT_YET_RECRUITING

Los Angeles, California, 90024, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Alabama Medical Center
NOT_YET_RECRUITING

Birmingham, Alabama, 35294, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Cincinnati
NOT_YET_RECRUITING

Cincinnati, Ohio, 45267, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Wisconsin - Madison
NOT_YET_RECRUITING

Madison, Wisconsin, 53726, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Washington University
NOT_YET_RECRUITING

St Louis, Missouri, 63110, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.